The 16 linked references in paper F. Dzgoeva U., M. Sopoev ., T. Bestaeva ., O. Khamitsaeva ., S. Ktsoeva ., R. Sageeva ., E. Salamova ., Ф. Дзгоева У., М. Сопоев Ю., Т. Бестаева Л., О. Хамицаева В., С. Кцоева А., Р. Сагеева О., Э. Саламова Э. (2016) “Взаимоевязь кардиоваскулярных осложнений и нарушений костно-минерального метаболизма у больных на гемодиализе // The relationship of cardiovascular complications and disorders of bone mineral metabolism in patients on hemodialysis” / spz:neicon:nefr:y:2016:i:5:p:16-23

  1. Kendrick J, Cheung AK, Kaufman JS et al. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 2011;22:1913-1922. doi: 10.1681/ ASN.2010121224.
  2. Wolf M. Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol 2010;21:1427-1435. doi: 10.1681/ASN.2009121293.
  3. Isakova TIxJ, Sprague SM, Raphae K et al. Rationale and approaches to phosphate and fibroblast growth factor 23 reduction in CKD. Journal of the American Society of Nephrology 2015;26(10):2328-2339 doi:10.1681/ASN.2015020117
  4. Foley RN, Parfrey PS, Harnett JD. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995;47:186-192. doi: 10.1038/ki.1995.22
  5. Hassan A, Durlacher K, Silver J et al. The fibroblast growth factor receptor mediates the increased FGF23 expression in acute and chronic uremia Am J Physiol Renal Physiol 2016 ;310(3):F21721. doi: 10.1152/ajprenal.00332.2015
  6. Mathew JS,Sachs MC, Katz R et al. Fibroblast growth factor-23 and incident atrial fibrillation: The Multi-Ethnic Study of Atherosclerosis (MESA) and the Cardiovascular Health Study (CHS). Circulation 2014;130:298-307. doi:10.1161/CIRCULATIONAHA.113.005499.
  7. Felsenfeld AJ, Levine BS, Rodriguez M. Pathophysiology of Calcium, Phosphorus, and Magnesium Dysregulation in Chronic Kidney Disease. Semin Dial 2015;28(6):564-577. doi: 10.1111/sdi.12411
  8. Mace ML, Gravesen E, Hofman-Bang J et al. Key role of the kidney in the regulation of fibroblast growth factor 23. Kidney Int 2015; 88: 1304–1313. doi: 10.1038/ki.2015.231
  9. Jimbo R, Kawakami-Mori F, Mu S et al. Fibroblast growth factor 23 accelerates phosphate-induced vascular calcification in the absence of Klotho deficiency. Kidney Int 2014;85:11031111. doi:10.1038/ki.2013.332
  10. Cozzolino M, Cosa F, Ciceri F et al. Vascular calcification in chronic kidney disease. EMJ Neph 2013;1:46-51. doi: 10.1016/j. advms.2015.09.004.
  11. Kurnatowska I, Grzelak P, Kaczmarska M et al. Serum osteoprotegerin is a predictor of progression of atherosclerosis and coronary calcification in hemodialysis patients. Nephron Clin Pract 2011; 117:297-304. doi: 10.1159/000321169.
  12. Hsu JJ, Katz R, Ix J et al. Association of fibroblast growth factor-23 with arterial stiffness in the Multiethnic Study of Atherosclerosis (MESA). Nephrol Dial Transplant 2014;29:2099-2105. doi: 10.1093/ndt/gfu101
  13. Smith ER, Ford ML, Tomlinson LA et al. Serum Calcification Propensity Predicts All-Cause Mortality in Predialysis CKD.JASN 2014; 25: 339-348. doi: 10.1681/ASN.2013060635
  14. Isakova Т. An Introduction to PTH, Phosphate and Vitamin D: Current Issues and Concerns Seminars in Dialysis. 2015;28(6):563. doi:10.1111/sdi.12445
  15. Scialla JJ, Rahman M. Fibroblast Growth Factor-23 and Cardiovascular Events in CKD. J Am Soc Nephrol 2014; 25: 349360. doi: 10.1681/ASN.2013050465
  16. Faul C, Amaral AP, Oskouei B. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011;121:4393-4408. doi: 10.1172/JCI46122 Сведения об авторах: Проф. Дзгоева Фатима Урузмаговна